Clinical Trials
19 trialsA Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
TRIUNITE06
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
FUTURE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Tislelizumab in People With Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer
Fudan University
Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients
Fudan University
SMALLER
Sun Yat-sen University
Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases
The First Affiliated Hospital with Nanjing Medical University
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Sun Yat-sen University
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
DETECT
Sun Yat-sen University
REFIT-MSS
Translational Research in Oncology
MYPHISMO
Peter MacCallum Cancer Centre, Australia
Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer
The First Affiliated Hospital with Nanjing Medical University
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Zhejiang Cancer Hospital
The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)
Fudan University